Featured

MAIT cells: linking the gut microbiome to antitumor immunity?

In patients with colon adenocarcinoma, high infiltration by mucosa-associated invariant T (MAIT) cells – which can be activated by a wide variety of bacteria and recognize epitopes presented by the MHC-like molecule using a limited set of invariant...

Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

Basher et al. showed that B10G5, an antibody able to clear soluble human NKG2D ligand (sMIC), synergized with anti-PD-L1. Co-therapy inhibited growth of sMIC+PD-L1+ melanoma to promote survival in syn...

CD4+ T-cell killing of multiple myeloma cells is mediated by resident bone marrow macrophages

Using myeloma mouse model, Haabeth and Henning et al. show, with adoptive transfer or TCR-transgenic (TCR-Tg) mice, that tumor-specific CD4+ T cells elicit antitumor immune response in the bone marrow...

A rational mouse model to detect on-target off-tumor CAR T cell toxicity

To address on-target, off-tumor toxicity with CAR T cell therapy, Castellarin et al. developed a model in which hHER2 was stably expressed at high (hHER2-high) or low (hHER2-low) levels on normal hepa...

Structure-guided engineering of the affinity and specificity of CARs against Tn-glycopeptides

Using a deep mutational scan, Sharma et al. showed that the 237-antibody, which binds to Tn antigen – a cancer-specific, aberrantly O-glycosylated epitope of a murine protein (OTS8) – is affected by t...

See all for this week

Previous Digests

Messenger for DCs: vesicles spread tumor antigens across dendritic cell subsets

June 17, 2020

It is well known that the initiation of an antitumor T cell response begins with priming by dendritic cells (DCs) inside the tumor-draining lymph node (TDLN). But how do migratory DCs, which pick up antigens at the tumor site...

CD4+ T cells take center stage in bladder cancer

June 11, 2020

Bladder cancer is often resistant to anti-PD-1 immunotherapy, however, responses do occur in a small fraction of patients. In order to better understand the specific T cells that mediate tumor rejection in those infrequent cases, Oh and Kwek et...

Flt3L-armored T cells engage the immune system to fight solid cancers

June 3, 2020

As tumor antigen heterogeneity limits the efficacy of engineered TCR and CAR T cells against solid tumors, Lai and Mardiana et al. engineered T cells that express and secrete the dendritic cell (DC) growth factor Flt3L in order to...

See More Digests

Everything New In...

Experimental Immunotherapy

Innovative Methods

Cancer Immunobiology

Popular Tags

About ACIR

ACIR's mission is to fast-track Cancer Immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

More About Us

The field of cancer immunotherapy has exploded in recent years, drawing on the creativity and experience of scientists, clinicians, and patient advocates. ACIR does an incredible job of bringing these groups together toward a common goal of eliminating cancer by disseminating important research findings to the community at large.

— James Allison, PhD

Professor and Chair, Department of Immunology; Executive Director, Immunotherapy Platform; Director, Parker Institute for Cancer Immunotherapy; and Vivian L. Smith Distinguished Chair-Immunology at the University of Texas MD Anderson Cancer Center. 2018 Nobel Prize in Physiology or Medicine.

As a researcher bridging the science and clinical translation of the exciting discoveries of cancer immunotherapy, I applaud the efforts of ACIR to help me, my post-docs and students, and my colleagues keep up to date on all the key innovations driving this field. New knowledge continually refines our current thinking and ACIR keeps that new knowledge fresh and at our fingertips.

— Catherine Wu, MD, PhD

Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School; Institute Member, Broad Institute of Harvard and MIT

There is a critical need to provide reliable information to physicians and researchers. Key limitations are the large amount of data that is being published and the multiple clinical trials available. I welcome the efforts by ACIR to make sense out of all this data and provide a reliable source of information for researchers in cancer immunotherapy.

— Antoni Ribas, MD, PhD

Professor of Medicine, Surgery, Molecular and Medical Pharmacology at the University of California (UCLA); Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC); Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA

The work of ACIR is so beautifully targeted on something that has the potential of being truly useful even in the earliest stages. What a great idea!

— John Petricciani, MD

President of the International Alliance for Biological Standardization (IABS); Former Director of the Center for Biologics at FDA and former Chief Medical Officer of the Biologicals Unit at WHO

Our understanding of the interaction between the immune system and cancer cells, and also the ways to exploit this interaction clinically, is growing faster than ever before. There is no reliable source of information that can help clinicians and researchers in this field stay up-to-date, and by filling this gap, ACIR facilitates the development of effective cancer immunotherapies for an increasing number of patient groups.

— Ton Schumacher, PhD

Deputy Director of the Netherlands Cancer Institute; Professor of Immunotechnology at Leiden University, The Netherlands; Chief Scientific Officer of Kite Pharma EU; SU2C-CRI Immunotherapy Dream Team member

Cancer Immunotherapy is providing patients with novel and durable treatments and the number of available therapies keeps growing. The mission of ACIR is to accelerate the pace by which the field develops through mapping out the research and clinical landscapes and keeping track of key advances in the field. It has my total support!!

— Robert D. Schreiber, PhD

Alumni Endowed Professor of Pathology and Immunology and Professor of Molecular Microbiology at Washington University School of Medicine, MO; Director of the Washington University Center for Human Immunology and Immunotherapy Programs; Associate Director of the Scientific Advisory Board to the CRI

I fully support the important initiative of ACIR. The field of cancer immunotherapy grows at an exciting pace. Staying on top of foundational discoveries in the field, which is conveniently processed on ACIR, is key for coming up with important new hypotheses about immunotherapeutic cancer treatment strategies.

— Glenn Dranoff, MD, PhD

Global Head of Immuno-Oncology, Novartis Institutes of BioMedical Research

I fully endorse the mission of ACIR to provide a weekly synopsis of the scientific literature in cancer immunotherapy. The value of this approach has been clearly demonstrated by a program I have been involved in with the Prize4Life Foundation, which is dedicated to curing ALS. ALS Forum provides ALS research summaries as well as other content related to clinical trials and is widely used by the ALS research community to keep up to date.

— Tom Maniatis, PhD

Chairman of the Department of Biochemistry and Molecular Biophysics at the Columbia University Medical Center (CUMC) in New York, and Director of the University wide Columbia Precision Medicine Initiative (CPMI)

ACIR has identified a great way to meet the critical need of researchers and clinicians everywhere to stay up to date with the literature in the fast moving and life-saving field of cancer immunotherapy. This will be a fine living tribute to your son Matt and has the potential to help many future cancer victims!

— James S. Economou, MD, PhD

Beaumont Professor of Surgery, Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA)

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

— Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

Featured

In the Spotlight...